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In this issue of Cell Stem Cell, Buckley et al. (2012) show that the ubiquitin-proteasome system (UPS)
regulates pluripotency in embryonic stem cells and induced pluripotent stem cells, opening the door to
a better understanding at the system level of protein dynamics responsible for themaintenance and induction
of pluripotency.Cellular pluripotency, differentiation, and
reprogramming together have constituted
one of the most attractive fields in biology
and medicine (Graf, 2011). Despite being
the focus of intense attention, the molec-
ular mechanisms that regulate pluripo-
tency and reprogramming remain largely
unclear (Yamanaka, 2012). Many compre-
hensive studies have attempted to shed
light on underlying mechanisms at the
levels of the epigenome, transcriptome,
and proteome, but the resulting data
sets have not been sufficient to delineate
the protein dynamics required for pluripo-
tency, in part because posttranslational
modifications such as ubiquitylation also
play important and complex roles in the
control of protein abundance and function
(Lu et al., 2009).
The ubiquitin-proteasome system
(UPS) mediates the rapid and highly spe-
cific degradation of intracellular proteins
and thereby contributes to the dynamic
regulation of protein abundance (Hershko
and Ciechanover, 1998). Control of pro-
tein abundance by the UPS comprises
two discrete steps: the covalent attach-
ment of multiple ubiquitin molecules to
lysine residues of the protein substrate,
and degradation of the polyubiquitylated
protein by the 26S proteasome complex.
The rapidity and specificity of proteolysis
mediated by this system underlie pro-
nounced changes in the cellular state
such as those associated with progres-
sion through the cell cycle, signal trans-
duction, and circadian rhythms. It is
therefore not hard to imagine that the
UPS might also govern the transition
from pluripotent to differentiated states
in embryonic stem cells (ESCs) or the
reverse process in induced pluripo-
tent stem cells (iPSCs). Aifantis and728 Cell Stem Cell 11, December 7, 2012 ª2colleagues have now provided an over-
view of the ubiquitylated protein land-
scape, or ‘‘ubiproteome,’’ in ESCs and
iPSCs and have found that certain com-
ponents of the UPS regulate pluripotency.
Indeed, their results indicate that the UPS
constitutes a major level of regulation of
cell pluripotency and reprogramming.
To encompass the whole picture re-
lating to the role of ubiquitylated proteins
in the regulation of pluripotency, Aifantis
and coworkers applied both biochemical
and genetic approaches (Figure 1). With
regard to the former, they took advantage
of antibodies that recognize lysine resi-
dues of protein substrates that have
been modified by two tandem glycine
residues of ubiquitin in order to enrich
ubiquitylated peptides. Analysis of the
enriched peptides by liquid chromatog-
raphy and tandem mass spectrometry
(LC-MS/MS) identified >1,000 proteins in
mouse ESCs in the pluripotent or differen-
tiated states and revealed that many well-
characterized members of the extended
pluripotency network, such as Oct4 and
Nanog, are themselves ubiquitylated in
the pluripotent cells. The half-lives of
Oct4 and Nanog proteins in pluripotent
ESCs are on the order of only a few hours,
suggesting that the abundance of these
key regulators of pluripotency is strictly
controlled by their production and by
UPS-mediated degradation. This notion
is consistent with the previous observa-
tion that either an increase or a decrease
of >50% in the amount of Oct3/4 pro-
motes the differentiation of ESCs (Niwa
et al., 2000). It is also intriguing that
many epigenetic modulators—including
Dnmt3a, Jmjd1, and Setdb1—were found
to be ubiquitylated in pluripotent ESCs,
suggesting that the abundance of many012 Elsevier Inc.of the key players in the induction or
maintenance of pluripotency is largely
dependent on the UPS.
In addition to this proteomics strategy,
Aifantis and colleagues cleverly adopted
two opposite approaches to genetic
screening for the identification of UPS
components that are responsible for the
maintenance of pluripotency or for the
induction of differentiation. The fluores-
cence intensity of green fluorescent pro-
tein (GFP) expressed under the control
of the Nanog gene promoter in ESCs
was used as an indicator of pluripotency.
To identify proteins required for the main-
tenance of pluripotency, the researchers
transfected the GFP-expressing pluripo-
tent ESCs with small interfering RNAs
(siRNAs) specific for 640 UPS factors
and monitored GFP fluorescence. One
of the proteins whose siRNA-mediated
depletion abrogated pluripotency most
dramatically was Psmd14, a deubiquity-
lating enzyme that resides in the 19S
‘‘lid’’ of the proteasome. Indeed, the
deubiquitylating activity of this enzyme
was found to be required together with
proteasomal activity for the maintenance
of pluripotency in ESCs. Consistent with
this finding, Psmd14 is expressed at a
high level in pluripotent ESCs, whereas
its expression is downregulated as the
cells differentiate. Depletion of Psmd14
also blocked the generation of iPSCs
from differentiated cells. These results
thus suggest that Psmd14 plays a
pivotal role in the control of pluripotency
regulators. Psmd11, another component
of the 19S proteasome lid, was also
recently shown to be essential for pluripo-
tency in human ESCs (Vilchez et al.,
2012). Although the detailed mechanisms
by which proteasomal activity controls
AD
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Figure 1. Strategies Used to Identify Pluripotency Maintenance Factors and Lineage Differentiation Factors
(A) Biochemical strategy to delineate the landscape of ubiquitylated proteins associated with the pluripotent or differentiated states in ESCs. Ubiquitylated
proteins of differentiated or pluripotent ESCs are immunoprecipitated with antibodies to diglycine-modified lysine residues and are identified by LC-MS/MS.
(B) Genetic approach to identify key regulators responsible for the maintenance of pluripotency, whose siRNA-mediated depletion results in a decrease in the
fluorescence intensity of GFP expressed under the control of the Nanog gene promoter.
(C) Genetic strategy to identify key regulators responsible for the induction of differentiation in ESCs.
(D) Fbxw7 and Psmd14 are necessary for ESCs to differentiate and maintain pluripotency, respectively.
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these observations support the notion
that the UPS is essential for the mainte-
nance of pluripotency in ESCs and for its
induction in iPSCs.
Adopting the opposite genetic ap-
proach, Aifantis and coworkers set out
to identify UPS components that block
pluripotency. To this end, they cultured
the GFP-expressing ESCs under dif-
ferentiation-inducing conditions and then
transfected them with the UPS-targeted
siRNAs. Depletion of certain UPS factors
was found to attenuate differentia-
tion and to promote pluripotency in the
ESCs. Among these latter proteins, the
researchers focused on the F-box protein
Fbxw7, a substrate-recognition subunit of
the SCF-type E3 ubiquitin ligase complex.
Although Fbxw7 is known to target many
transcriptional activators and cancer-
associated proteins—including c-Myc,Notch, cyclin E, c-Jun, KLF5, SREBP,
PGC-1a, mTOR, Mcl-1, and NF-kB2
(Welcker and Clurman, 2008)—compre-
hensive identification of Fbxw7 sub-
strates with a differential proteomics
approach revealed that the spectrum of
proteins targeted by Fbxw7 differs
substantially among cell types (Yumimoto
et al., 2012). Buckley et al. found that
depletion of Fbxw7 resulted in stabiliza-
tion of c-Myc and a consequent increase
in the amounts of the pluripotency factors
Nanog, Oct3/4, and Sox2. These effects
both inhibited the differentiation of ESCs
and enhanced the efficiency of iPSC
generation. Additional depletion of c-Myc
antagonized the effect of Fbxw7 depletion
in ESCs, suggesting that the Fbxw7-c-
Myc axis is a key determinant of pluripo-
tency in these cells. However, based on
our findings, such is not the case in iPSCs:
we discovered that additional depletion ofCell Stem Cell 11,c-Myc did not affect the promotion
of iPSC generation induced by loss of
Fbxw7, suggesting that another Fbxw7
substrate or substrates contribute to
the reprogramming process (Okita et al.,
2012).
The findings of Aifantis and coworkers
thus together indicate that the UPS,
including Psmd14 and Fbxw7, plays
essential roles in the maintenance of plu-
ripotency and induction of differentiation
in ESCs, as well as in the cellular reprog-
ramming process, by influencing multiple
pathways (Figure 1). Although this paper
is highly significant in that it provides
the first characterization of the ‘‘ubipro-
teome’’ in ESCs and demonstrates the
requirement of the UPS for pluripotency,
there remains a large gap between the
results of the proteomics and genetic
approaches in the study. This gap will
be filled by examination of individualDecember 7, 2012 ª2012 Elsevier Inc. 729
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Previewsimplicated proteins in future studies. An
understanding of the entire regulatory
network for pluripotency and reprogram-
ming from the viewpoint of protein
dynamics should facilitate the develop-
ment of new methods for more efficient
and safer reprogramming that will help
realize potential medical applications
for iPSCs.
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Two studies in this issue of Cell Stem Cell highlight context-dependent roles for MSCs in controlling tumor
growth. Lee et al. (2012) show that preactivated MSCs have antitumor effects upon adoptive transfer in vivo,
and Ren et al. (2012) show that tumor-resident MSCs can promote tumor growth by influencing macro-
phages.Inflammation is a key component of the
tumor microenvironment (Hanahan and
Weinberg, 2011; Mantovani et al., 2008).
The ecological niche of a tumor includes
inflammatory cells and mediators that
generally promote tumor progression
(Mantovani et al., 2008). Tumor-associ-
ated macrophages (TAMs) are a major
component of the leukocyte infiltrate
present in neoplastic tissues and play
a key role in cancer-related inflammation
through several different mechanisms,
including stimulation of angiogenesis,
promotion of growth, invasion andmetas-
tasis, and inhibition of antitumor immune
responses. Mesenchymal stromal/stem
cells (MSCs) are also present in tumor
stroma. In the tumor microenvironment,
stroma provides more than scaffolding
and MSCs are thought to act as precur-
sors for cancer-associated fibroblasts
(CAFs) (reviewed in Servais and Erez,2012). Together, MSCs and CAFs engage
in bidirectional interactions with cancer
cells and macrophages, which promote
tumor growth (Servais and Erez, 2012).
Two reports in this issue of Cell Stem
Cell shed new light and raise questions
on the role of MSCs in tumor progression
(Lee et al., 2012; Ren et al., 2012).
Lee et al. (2012) extend previous
studies on the antitumor activity of
MSCs expressing the proapoptotic mole-
cule TRAIL (e.g., Menon et al., 2009). They
report that MSCs that are preactivated by
inflammatory cytokines, TNF in particular,
or via activation of TLR3, express TRAIL
and have in vitro antitumor activity against
several human tumor cell lines by induc-
ing apoptosis. They also analyzed the
in vivo behavior of the TRAIL-expressing
MSCs in a xenograft model using a human
breast carcinoma cell line injected intra-
venously. They found that adoptive celltherapy with preactivated MSCs reduced
the size of tumor lesions in the lungs
and increased tumor cell death in situ.
In vitro, TNF-activated MSCs synergized
with doxorubicin, an anticancer drug, in
causing apoptotic cell death of breast
cancer cells. TNF-activated MSCs also
caused inhibition of cell cycle progression
in the breast carcinoma cells, a finding
presumably related to induction of the
cell cycle inhibitor Dickkopf3 (DKK3),
which is likely to contribute to the anti-
tumor activity in vivo (Figure 1).
In a separate paper, Ren et al. (2012)
dissect the tumor-promoting function of
MSCs using a primary mouse lymphoma
model, which was a major strength of
this study. To study tumor-resident
MSCs, they took advantage of sponta-
neous lymphomas developing in p53,
FasL, or MutL homolog-deficient mice.
The authors isolated the lymphomas,
